SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 8, 1999
UNIMED PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-3390 22-1685346
(State or other (Commission File Number) (IRS Employer
Jurisdiction of Identification No.)
Incorporation)
2150 E. LAKE COOK RD.
BUFFALO GROVE, ILLINOIS 60089
(Address of Principal Executive Office) (Zip Code)
Registrant's telephone number, including area code: (847) 541-2525
NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
Incorporated by reference to Press Release by Unimed Pharmaceuticals,
Inc. dated February 8, 1999.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS.
(A) FINANCIAL STATEMENTS OF THE BUSINESS ACQUIRED
Not Applicable.
(B) PRO FORMA FINANCIAL INFORMATION
Not Applicable.
(C) EXHIBITS
EXHIBIT NO. DOCUMENT
17.1 Press Release dated February 8, 1999 by
Unimed Pharmaceuticals, Inc.{1}
**FOOTNOTES**
{1} Filed herewith.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
UNIMED PHARMACEUTICALS, INC.
(Registrant)
By: /S/ DAVID E. RIGGS
David E. Riggs, Chief Financial
Officer
Dated: February 19, 1999
(UMED) UNIMED PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
Business Editors
Buffalo Grove, Ill - (BUSINESS WIRE) - Feb. 8, 1999 -
Dr. Ronald L. Goode Resigns; Dr. Robert E. Dudley Elected New
President and CEO
Unimed Pharmaceuticals, Inc. today announced the resignation of Dr.
Ronald L. Goode as President and CEO and the election of Dr. Robert E.
Dudley to both positions. Dudley, 44, joined Unimed in 1994 and has been
Senior Vice President in charge of the company's clinical development,
regulatory affairs and manufacturing efforts. He has also been responsible
for a specialized marketing group. For most of 1997, Dudley served as
interim President and CEO of Unimed.
Commenting on the change, Dr. John Kapoor, Chairman of the Unimed
Board of Directors, said, "Unimed is a stronger company as a result of Dr.
Goode's leadership in business and product development and in building an
excellent management organization. We are confident that Bob Dudley and
his team will maintain and enhance the company's strategic direction."
Unimed is an emerging, Chicago-area pharmaceutical company that
develops and markets life-enhancing pharmaceutical products to address
unmet medical needs in patients with chronic conditions. The company
focuses on drugs that have multiple indications and fall within the areas
of endocrinology, urology, HIV and other infectious diseases, hematology
and oncology.
Unimed currently markets Marinol (R) (dronabinol) as an appetite
stimulant for people living with HIV disease and as an antiemetic for
people with cancer, Anadrol (R)-50 (oxymetholone) for the treatment of
various anemias, and Maxaquin (R) (Iomefloxacin HCI) for both complicated
and uncomplicated urinary tract infections. For more information, please
view our website at www.unimed.com.
